threonine has been researched along with delanzomib in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 19 (90.48) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Allievi, C; Berkers, C; Bernareggi, A; Bussolati, B; Camussi, G; Cassin, M; Coscia, M; Costa, G; de Feudis, P; di Giovine, S; Ferracini, R; Ferrero, D; Giai, V; Hunter, K; Inghirami, G; Jones-Bolin, S; Massaia, M; Neri, A; Nicoli, P; Ovaa, H; Palumbo, A; Peola, S; Pescalli, N; Pezzoni, G; Piva, R; Roato, I; Ruggeri, B; Strepponi, I; Tamagno, I; Williams, M; Zhao, H | 1 |
| Berenson, JR; Bonavida, B; Chen, H; Li, M; Li, ZW; Sanchez, E; Shen, J; Steinberg, JA; Wang, C | 1 |
| Bagnati, R; Cereda, R; D'Incalci, M; Livi, V; Marangon, E; Sala, F; Zucchetti, M | 1 |
| Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M | 1 |
| Appel, A | 1 |
| Lu, LD; Ruggeri, BA; Seavey, MM; Stump, KL; Wallace, NH | 1 |
| Gallastegui, N; Groll, M | 1 |
| Berenson, JR; Chen, H; Hunter, K; Jones-Bolin, S; Li, J; Li, M; Ruggeri, B; Sanchez, E; Wang, C | 1 |
| Böhm, S; Brunelli, D; Cereda, R; D'Incalci, M; De Braud, F; Delmonte, A; Driessen, C; Gallerani, E; Hess, D; Marangon, E; Marsoni, S; Martinelli, G; Noberasco, C; Sala, F; Sessa, C; Zucchetti, M | 1 |
| Hu, Y; Wu, P; Zhang, J | 1 |
| Antoniadi, G; Eleftheriadis, T; Liakopoulos, V; Pissas, G; Stefanidis, I | 2 |
| Hiepe, F; Radbruch, A | 1 |
| Kłoczko, J; Ołdziej, AE; Romaniuk, W; Zińczuk, J | 1 |
| Bourenkov, G; Chari, A; Henneberg, F; Mata, RA; Schneider, TR; Schrader, J; Stark, H; Tittmann, K | 1 |
| Bocchia, M; Brambilla, CZ; Candi, V; Gozzetti, A; Papini, G; Sirianni, S | 1 |
| Asano, T; Isono, M; Okubo, K; Sato, A | 1 |
| Hasinoff, BB; Patel, D | 1 |
| Hawkins, CJ; Patatsos, K; Shekhar, TM | 1 |
| Li, H; Liang, L; Liu, Z; Lu, J; Niu, Y; Shen, L; Shi, Z; Wang, M; Xu, X; Yan, Y; Yu, Y; Zhang, H; Zhao, Y | 1 |
| Agha, A; Ali, AA; Debiec-Rychter, M; Dhillon, HS; Duensing, A; Gebreyohannes, YK; Lee, DM; Makielski, KR; Mehalek, KR; Patil, SS; Rausch, JL; Schöffski, P; Tolstov, Y; Wellens, J; Wozniak, A | 1 |
6 review(s) available for threonine and delanzomib
| Article | Year |
|---|---|
Novel proteasome inhibitors to overcome bortezomib resistance.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination | 2011 |
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Threonine | 2013 |
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
Plasma cells as an innovative target in autoimmune disease with renal manifestations.
Topics: Autoantibodies; Autoimmune Diseases; B-Lymphocytes; Boronic Acids; Bortezomib; Glomerulonephritis; Humans; Immunologic Memory; Immunosuppressive Agents; Kidney Diseases; Lupus Nephritis; Oligopeptides; Peptides; Plasma Cells; Proteasome Inhibitors; Threonine | 2016 |
[Proteasome inhibitors in cancer therapy].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Dipeptides; Humans; Lactones; Multiple Myeloma; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrroles; Thiazoles; Threonine | 2015 |
Second Generation Proteasome Inhibitors in Multiple Myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Drug Discovery; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Threonine | 2017 |
1 trial(s) available for threonine and delanzomib
| Article | Year |
|---|---|
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Threonine | 2013 |
15 other study(ies) available for threonine and delanzomib
| Article | Year |
|---|---|
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Endothelial Cells; Enzyme Inhibitors; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Nude; Multiple Myeloma; Neoplasms; NF-kappa B; Osteogenesis; Proteasome Inhibitors; Pyrazines; RANK Ligand; Threonine; Treatment Outcome; Ubiquitin; Xenograft Model Antitumor Assays | 2008 |
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Threonine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study.
Topics: Acetonitriles; Biphenyl Compounds; Boronic Acids; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Drug Stability; Humans; Irbesartan; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tetrazoles; Threonine | 2010 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Topics: Animals; Antibodies, Antinuclear; Boronic Acids; Cytokines; Disease Models, Animal; Drug Administration Routes; Female; Kidney; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Spleen; Threonine | 2012 |
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine | 2012 |
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Thalidomide; Threonine; Xenograft Model Antitumor Assays | 2012 |
Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions.
Topics: Apoptosis; Boronic Acids; Cell Culture Techniques; Cell Hypoxia; Epithelial Cells; Humans; Kidney Tubules; Oligopeptides; Proteasome Inhibitors; Threonine | 2016 |
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Topics: Antineoplastic Agents; Biocatalysis; Boron Compounds; Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; Drug Design; Glycine; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Threonine | 2016 |
A comparative analysis between proteasome and immunoproteasome inhibition in cellular and humoral alloimmunity.
Topics: Antibody-Dependent Cell Cytotoxicity; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Graft Rejection; Histocompatibility; Humans; Immunity, Cellular; Immunity, Humoral; Immunosuppression Therapy; Isoantibodies; Kidney Transplantation; Leukocytes, Mononuclear; Lymphocyte Culture Test, Mixed; Oligopeptides; Proteasome Inhibitors; Threonine | 2017 |
Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Carcinoma, Renal Cell; Cell Line, Tumor; Cytochrome P-450 CYP3A Inhibitors; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Proteasome Inhibitors; Ritonavir; Threonine | 2018 |
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Topics: Animals; Animals, Newborn; Boron Compounds; Boronic Acids; Bortezomib; Cardiotoxicity; Cell Survival; Dose-Response Relationship, Drug; Epoxy Compounds; Glycine; Humans; K562 Cells; Ketones; Kinetics; Myocytes, Cardiac; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Rats, Sprague-Dawley; Threonine | 2018 |
Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bone Neoplasms; Boron Compounds; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Glycine; Humans; Oligopeptides; Osteosarcoma; Proteasome Inhibitors; Sulfonamides; Threonine | 2018 |
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Topics: Boronic Acids; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; MCF-7 Cells; Phosphorylation; Proteasome Inhibitors; Threonine; Tumor Suppressor Protein p53 | 2019 |
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Boronic Acids; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Oligopeptides; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Threonine; Xenograft Model Antitumor Assays | 2020 |